Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

Area of Science:

• Immunology
• Vaccinology
• Microbial Chemistry

Background:

• Monophosphoryl lipid A (MPLA) is an FDA-approved adjuvant derived from lipooligosaccharide (LOS).
• Existing lipid A adjuvants are limited despite numerous potential bacterial sources.
• There is a need for novel adjuvants to enhance vaccine efficacy against infectious diseases.

Purpose of the Study:

• To develop a method for generating functionally diverse lipid A molecules.
• To create novel LOS structures with differential Toll-like receptor 4 (TLR4) activation using bacterial enzymatic combinatorial chemistry (BECC).
• To identify lead candidates with potent immunostimulatory properties for vaccine development.

Main Methods:

• Bacterial enzymatic combinatorial chemistry (BECC) was used to reprogram lipid A biosynthesis in *Yersinia pestis*.
• Reporter cell lines measuring NF-κB activation were used to screen BECC-derived molecules for TLR4 activation.
• Cytokine secretion (TNF-α, IL-8) and immunostimulation in splenocytes, PBMCs, and dendritic cells were analyzed.

Main Results:

• BECC successfully generated structurally distinct LOS molecules.
• BECC-derived molecules exhibited dose-dependent, TLR4-driven NF-κB activation in human and mouse systems.
• Lead candidates induced cytokine levels comparable to PHAD and showed potent immunostimulation in various immune cells.

Conclusions:

• BECC is a viable method for directed programming of lipid A synthesis.
• This approach can generate a diverse array of TLR4 agonist candidates for potential use as vaccine adjuvants.
• The identified lead compounds demonstrate promising *in vitro* immune stimulatory activity for future vaccine applications.